Company news

Allarity Therapeutics, Inc. news in 2024

Allarity Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

November 17, 2024

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

November 13, 2024

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

October 21, 2024

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

October 9, 2024

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

October 2, 2024

Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial

September 15, 2024

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2024

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

September 10, 2024

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

July 25, 2024

Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

July 23, 2024

Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives

July 21, 2024

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

June 26, 2024

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

June 24, 2024

Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

May 19, 2024

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

May 13, 2024

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

May 6, 2024

Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1

May 5, 2024

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer

May 1, 2024

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

April 16, 2024

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

April 3, 2024

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

March 26, 2024

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

March 24, 2024

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

March 7, 2024

Allarity Therapeutics to Present at Biomarkers 2024

February 27, 2024

Decks in 2024